Current news and events

The Norwegian Cancer Society distributes NOK 183 mill NOK to 24 researchers

A total of just under NOK 183 million is now being distributed among 24 researchers, 13 of whom are affiliated to Oslo University Hospital. They were selected after independent international experts had assessed a total of 146 applications.
After the all-time fundraising record in the Pink Ribbon Campaign, more researchers than ever are receiving millions in support for vital work against breast cancer.  "Thanks to all the contributions from private individuals and businesses, from the hundreds of thousands who bought and wore the pink ribbon last year, we can now distribute a total of 47 million kroner to six outstanding breast cancer researchers", says Secretary General of the Norwegian Cancer Society, Ingrid Stenstadvold Ross.

The “Oslo patient” – probably cured of HIV

Photo: Grete Hansen, Bioingeniøren
Photo: Grete Hansen, Bioingeniøren

Mari Kaarbø, leader of the Virology Research Group at Oslo University Hospital, was interviewed by the journal Bioingeniøren after leading one of the research teams that collaborated on the “Oslo patient” project. Kaarbø has been primarily responsible for the careful examination of the patient’s blood and gut cells to identify HIV reservoirs. The patient has been off treatment and clinically virus‑free for nearly three years.

November 14th - December 19th:Photo exhibition about people with cancer at the Radium hospital

Sigrid S. Skånland, researcher at the Institute for Cancer Research, recently published the photo book “Mennesker med kreft = People with cancer”. The book portrays 50 people with cancer and includes short quotes from each participant, both in Norwegian and English. Skånland got the idea to do the photo project after being awarded the price “Researcher of the year” in 2023. The price money (100,000 NOK) was financed by Radiumhospitalets legater and had to be spent on cancer-related activity.

“I noticed that the stereotype of cancer patients presented to us by the media does not reflect the reality. I wanted to see and show what real people with cancer are like,” Skånland says.

Professor Ole Andreassen awarded international research prize

Dr. Ole Andeassen and Dr. Jeffrey Borenstein. Photo: Chad David Kraus
Dr. Ole Andeassen and Dr. Jeffrey Borenstein. Photo: Chad David Kraus

Andreassen receives the Colvin Prize for Outstanding Achievement in Mood Disorders Research for his groundbreaking research on bipolar disorder. The prize is awarded annually by the Brain & Behavior Research Foundation.  "It is a great honour for me to receive this international award in competition with researchers from all over the world. In the USA, the prize is well-known in the field," says professor Ole Andreassen, who is one of this year's five prize winners.
Andreassen was Norway's most publishing researcher in 2023 and 2024, as measured in publication points. 

Extensive presentation in major Norwegian newspaper VGGroundbreaking study attracts attention

From left: Eggebø, Olweus and Milek Nilsen. Photo: Line Møller, VG
From left: Eggebø, Olweus and Milek Nilsen. Photo: Line Møller, VG

A Norwegian research team led by Professor Johanne Olweus has developed a new and groundbreaking method that offers the possibility of treating several aggressive forms of cancer. In an article published in Nature Immunology they propose that TCR-T cells targeting CTNNB1-S37F can serve as a basis for solid cancer immunotherapy.
The results have attracted international attention, and the research was recently featured in a major article in Norway's largest newspaper VG, entitled "Norwegian cancer study: –⁠ This is definitely a breakthrough".

PREDI-LYNCH kickoff meeting in Heidelberg:Bringing Europe together to tackle Lynch syndrome

Mev Dominguez-Valentin welcomes the partners
Mev Dominguez-Valentin welcomes the partners

The PREDI-LYNCH consortium officially launched its six-year Horizon Europe project with an in-person kickoff meeting in Heidelberg on September 18, 2025. The partners were welcomed by Project Coordinator Mev Dominguez-Valentin from the Institute for Cancer Research.
The event brought together more than 50 researchers, clinicians, and partners from across Europe. Funded under the EU Mission on Cancer, PREDI-LYNCH unites leading institutions and experts to improve screening, diagnostics, and risk prediction for individuals with a hereditary predisposition to cancer.

Presentation of KLM’s Career Prize for outstanding researchPrize winners: Julie Elisabeth Heggelund and Rasmus Iversen

Iversen and Heggelund during the ceremony
Iversen and Heggelund during the ceremony

Julie Elisabeth Heggelund and Rasmus Iversen, both from the Department of Immunology at the Division for Laboratory Medicine (KLM), were recently awarded KLM's Career Prize for their outstanding early career research work. This award goes to researchers in the category of temporary employees, and was distributed for the first time in 2024. The evaluation committee consisted of three researchers from different KLM departments. The prize, amounting to 75.000 NOK, must be used to further research at OUS. Emma Lång, head of KLM TempAware, led the award ceremony together with her colleagues in the group, who represent the seven departments in KLM.

National Research Archive (NVA) Now Available for OUS Researchers

The National Research Archive (NVA) has replaced Cristin and is now open for both previous Cristin users and new contributors at OUS. Whether you're registering for the first time or updating your publications, NVA offers improved functionality for managing research outputs, including support for green open access and project code reporting.

Click More to learn how to get started, request editing access, and upload files for archiving.

Results published in NEJM and The Lancet:Beta-blockers reduce risk after heart attack

Dan Atar during his presentation at the ESC congress 2025
Dan Atar during his presentation at the ESC congress 2025

The Norwegian-Danish BETAMI-DANBLOCK study shows that beta-blockers still provide clear health benefits after a heart attack – even in patients with normal or slightly reduced heart function. The study included over 5,600 patients who had recently had a heart attack within the past fourteen days.

Professor Dan Atar presented the results as "Hot Line" findings at the European Cardiology Congress (ESC) in Madrid (33.000 participants) on August 30 2025. At the same time, they were simultaneously published in the prestigious journals New England Journal of Medicine and The Lancet.

More news from the archive